The clinical management of neuropathic pain

Dwight E Moulin MD FRCP(C) Neurology


Chronic neuropathic pain as a result of injury to the central or peripheral nervous system is common in clinical practice, and is especially predominant in the elderly. The present review summarizes the epidemiology, clinical features, pathophysiology, differential diagnosis and management of neuropathic pain and specifically details an evidence-based approach to the pharmacological treatment of this disabling condition. Preventive strategies and novel treatment approaches are required to improve the management of neuropathic pain.

Key Words: Neuropathic pain; Pharmacological management

Neuropathic pain is defined by the International Association for the Study of Pain as pain “initiated or caused by a primary lesion or dysfunction in the nervous system” (1). Neuropathic pain is a challenging clinical problem, because it is usually persistent, severe and resistant to conventional analgesics such as nonsteroidal anti-inflammatory drugs (2). It can be caused by lesions of the peripheral or central nervous system, or both. Sensory nerve injury usually results in numbness and sensory deficit in the territory of the involved nerve. Fortunately, pain is an unusual manifestation of nerve injury and there are few predictors to indicate which patients will develop this complication. For instance, 50% of diabetic patients develop neuropathy during the course of their illness, but only approximately 10% report actual dysesthesias or pain (3). Similarly, breast surgery with transection of the intercostal brachial nerve results in neuropathic pain in only 20% of patients (4).

Prevalence estimates suggest that 1% to 2% of Americans suffer from neuropathic pain, which suggests that at least half a million Canadians have this disabling condition (5,6). However, the prevalence of neuropathic pain is increasing because the population is aging, and several neuropathic pain syndromes, including diabetic neuropathy and postherpetic neuralgia, are more common in elderly patients. In addition, cancer patients are living longer (7) and many of the treatments used in the management of cancer, including chemotherapy, can cause neuropathic pain.

CLINICAL FEATURES AND PATHOPHYSIOLOGY OF NEUROPATHIC PAIN

The clinical features of neuropathic pain can be divided into spontaneous pain and stimulus-evoked pain. These sensations usually arise from the territory of the injured nerve, but they can radiate into adjacent, normally innervated, areas. Spontaneous pain is commonly described as burning, icy, or intense tightness with superimposed shooting or lancinating pain. Stimulus-evoked pain includes allodynia, which is pain in response to a normally nonpainful stimulus, and hyperalgesia, defined as increased pain in response to a normally painful stimulus. Various forms of allodynia can be demonstrated in the clinical setting. Dynamic allodynia can be elicited by flicking one or more hairs on the skin surface. Thermal allodynia can be demonstrated by applying an ice cube to the affected area – the paradoxical sensation of heat or burning is a classical feature of nerve injury. Repeated mechanical stimuli such as light touch may build into an explosive pain over several seconds and radiate beyond the territory of the injured nerve. These features illustrate temporal and spatial summation of the stimulus and this is referred to as hyperpathia. Superimposed autonomic features, such as alterations in temperature, colour and sweating, and the development of trophic changes, provide a diagnosis of reflex sympathetic dystrophy or complex regional pain syndrome (8).
There are several mechanisms responsible for pain following nerve injury, and they are based on peripheral and central sensitization of the nervous system (9,10). After peripheral nerve injury, sodium channels accumulate along the length of the axon, at sites of neuroma formation and in the dorsal root ganglia. These sodium channels are hyperexcitable and are the foci of ectopic impulse formation. In addition to firing spontaneously, these sites are sensitive to mechanical stimulation and local catecholamines, and are capable of generating prolonged discharges. Sprouting of sympathetic nerves into dorsal root ganglia may provide another mechanism for sympathetically maintained pain.

Peripheral nerve injury also generates secondary central sensitization at the spinal cord level due to excitatory and inhibitory mechanisms. Prolonged and repetitive discharges in primary afferent neurons produce progressive increases in dorsal horn neuronal discharges that can become autonomous. This is a major cause of central sensitization and is referred to as ‘wind-up’ in the dorsal horn. This phenomenon is mediated by the release of excitatory neurotransmitters, such as glutamate, from the primary afferent terminal and is facilitated by upregulation of voltage-gated calcium channels responsible for neurotransmitter release (11). Glutamate acts on various receptors in the dorsal horn, including the N-methyl-D-aspartate (NMDA) receptor, to produce central sensitization. Allodynia and hyperpathic phenomena such as temporal and spatial summation can be explained by the convergence of low threshold sensory afferents on sensitized wide dynamic range dorsal horn neurons. Conversely, actual transection of primary afferent neurons may reduce the amount of inhibitory input to the spinal cord and lead to dorsal horn hyperexcitability through deafferentation. The fact that there are multiple generators of neuropathic pain following nerve injury provides a rationale for polypharmacy rather than monotherapy in the management of neuropathic pain, because it may be necessary to target several pain mechanisms. It is also clear that none of the generators of neuropathic pain are disease-specific.

DIFFERENTIAL DIAGNOSIS OF NEUROPATHIC PAIN
The differential diagnoses of neuropathic pain are extensive, and include central and peripheral causes (Table 1). Examples of central neuropathic pain include poststroke pain (thalamic pain syndrome) and pain due to spinal cord injury. Common causes of spinal cord injury may include trauma and the demyelinating lesions of multiple sclerosis. Painful peripheral neuropathy can be divided into focal neuropathies, multifocal neuropathies and symmetrical polynuropathies.

The diagnosis of neuropathic pain is based primarily on the history and physical examination. Postherpetic neuralgia and painful diabetic neuropathy are usually easy to diagnose when there is a history of shingles and diabetes mellitus, respectively. However, pain radiating into an extremity can be either referred myofascial or neuropathic pain, and can be difficult to differentiate. A 10-item questionnaire based on sensory descriptors and sensory examination has been developed to differentiate between somatic and neuropathic pain. This instrument has been shown to be a valid and reliable discrimantor of neuropathic pain (12). In addition, the presence of true weakness (sometimes difficult to differentiate from pain-related or antalgic weakness), dropped reflexes, allodynia and hyperalgesia would all favour a diagnosis of neuropathic pain. Electromyography and nerve conduction studies are sometimes useful to provide more objective evidence of nerve injury. Imaging, such as computed tomography and magnetic resonance imaging, can confirm the presence of structural disease involving one or more nerve roots or the brachial or lumbosacral plexus. It is important to diagnose structural disease. For instance, nerve root impingement from disc herniation may be amenable to surgical decompression. Tumor infiltration of nerve often responds to targeted radiation therapy.

PHARMACOLOGICAL MANAGEMENT OF NEUROPATHIC PAIN
Because neuropathic pain is usually unrelenting, treatment goals have to be realistic. It is important to convey to the patient that the primary goal in most cases is to bring the pain into a tolerable range, not to eliminate the pain. It is also important to recognize and treat common comorbidities such as anxiety and depression. All of this targets the importance of secondary treatment goals of improved sleep and function, and overall improvement in quality of life.

Given that there are multiple generators of neuropathic pain that can vary from patient to patient and from one disease to the next, it follows that treatment must be individualized and that two or three agents may be required to target different pain mechanisms. However, decisions regarding first- and second-line drugs are still based on high-quality evidence of efficacy, side effect profile and cost-effectiveness. Because there is a lack of head-to-head trials to guide treatment choices, relative evidence of efficacy and safety can be gleaned from number needed to treat (NNT), the reciprocal of absolute risk reduction. NNT is defined as the number of patients that need to be treated with a certain drug to obtain one patient with at least 50% pain relief.

Antidepressants
Tricyclic antidepressants provide the best evidence of efficacy in the management of neuropathic pain. Although the definitive

<table>
<thead>
<tr>
<th>TABLE 1</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Classification of neuropathic pain</strong></td>
</tr>
<tr>
<td><strong>Class</strong></td>
</tr>
<tr>
<td>Central</td>
</tr>
<tr>
<td>Brain</td>
</tr>
<tr>
<td>Spinal cord</td>
</tr>
<tr>
<td>Multiple sclerosis</td>
</tr>
<tr>
<td>Peripheral</td>
</tr>
<tr>
<td>Focal</td>
</tr>
<tr>
<td>Carpal tunnel syndrome</td>
</tr>
<tr>
<td>Failed back syndrome with nerve root fibrosis</td>
</tr>
<tr>
<td>Multifocal</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
</tr>
<tr>
<td>Symmetrical</td>
</tr>
<tr>
<td>Ethanol abuse</td>
</tr>
<tr>
<td>Toxins (eg, vincristine)</td>
</tr>
</tbody>
</table>
mechanism of action of tricyclic analgesia is unknown, these drugs block the reuptake of noradrenaline and serotonin, block hyperalgesia induced by NMDA antagonists and also have sodium channel blocking properties (13). The tricyclics therefore have analgesic properties independent of their antidepressant effects.

Two systematic reviews (14,15) of antidepressants in neuropathic pain revealed a total of 17 randomized, controlled trials (RCTs) involving 10 antidepressants. The NNT was approximately three. There was no difference in NNT between tricyclic antidepressants with balanced reuptake of inhibition of serotonin and noradrenaline (amitriptyline, imipramine) and those with relatively selective inhibition of noradrenaline uptake (desipramine, nortriptyline). Similarly, in terms of NNT, the efficacy for tricyclic antidepressants was nearly identical regardless of the underlying condition (diabetes mellitus, herpes zoster, traumatic nerve injury or stroke). This suggests that the pathophysiology is similar in these varied conditions and that the etiology does not have a significant impact on therapeutic outcome.

The role of selective serotonin reuptake inhibitors in the management of neuropathic pain is controversial. Fluoxetine was not found to be efficacious in the management of diabetic neuropathy independent of its antidepressant effects (16), but paroxetine (17) and citalopram (18) were. However, the combined NNT for all three studies was 6.7 (19); therefore, selective serotonin reuptake inhibitors do not appear to be as efficacious as tricyclic antidepressants in the management of neuropathic pain.

The newer mixed serotonin noradrenaline reuptake inhibitors (SNRIs), venlafaxine and duloxetine, have an NNT of approximately four, indicating that they are more likely to be effective for neuropathic pain (20).

Anticonvulsants
Both carbamazepine (21) and phenytoin (22) have been shown to be useful in the management of diabetic neuropathy, with an overall NNT of 2.5 for effectiveness. However, there is only one RCT on each drug and these trials were of limited sample size – 30 patients in the carbamazepine trial and 12 patients in the phenytoin trial. Carbamazepine nevertheless remains the drug of first choice for trigeminal neuralgia with an NNT of 1.7 (20).

Gabapentin is an anticonvulsant that was approved by the United States in 1994 for the management of partial epilepsy. However, it has been used much more frequently in the management of neuropathic pain. Gabapentin is structurally related to gamma-aminobutyric acid (GABA), but it does not clearly have GABA properties. It binds to presynaptic voltage-gated calcium channels, and the mechanism of action is probably related to a reduction of release of excitatory neurotransmitters due to calcium channel blockade (23). There are eight randomized, double-blind, placebo-controlled trials of gabapentin for chronic neuropathic pain (24). The best known of these are two studies examining the management of painful diabetic neuropathy (25) and postherpetic neuralgia (26) using high-quality study designs. In both studies, gabapentin produced significant pain relief relative to placebo and there was also significant improvement in measures of quality of life and mood. The combined NNT for these two studies was approximately four.

Pregabalin is an analogue of gabapentin. It has the same mechanism of action, but manifests linear pharmacokinetics and has higher affinity for the presynaptic calcium channel. Several large RCTs have shown that pregabalin provides significant pain relief and improved quality of sleep in postherpetic neuralgia (27,28), painful diabetic neuropathy (29-31) or both (32). The overall NNT for pregabalin in these conditions is 4.2 (20). Pregabalin has also been studied in chronic central neuropathic pain following spinal cord injury with evidence of significant pain relief (33).

Lamotrigine is a novel anticonvulsant agent that has shown some benefit in the management of neuropathic pain. Lamotrigine may act through voltage-gated cation channels with inhibition of glutamate release. Lamotrigine has been found to be useful in the management of trigeminal neuralgia (34) and painful diabetic neuropathy (35). However, lamotrigine was not found to be useful in the management of a variety of peripheral neuropathic pain states (36). Lamotrigine also requires slow and careful titration and carries a risk of a potentially serious rash, including Stevens-Johnson syndrome.

Topiramate and valproate have produced mixed results in neuropathic pain trials (20).

Opioid analgesics
There is still considerable controversy surrounding the use of opioid analgesics for chronic neuropathic pain (37). The crucial factor in this controversy is the balance between analgesia and opioid-induced side effects. A pharmacokinetic-pharmacodynamic analysis of brief opioid infusions suggests that neuropathic pain responds to opioid drugs in a classic dose-dependent fashion, with a shift to the right in the dose-response curve (38). This contention was supported in a randomized, controlled, postoperative study that examined pain relief after thoracotomy using intravenous buprenorphine (39). The primary outcome measure was 50% pain relief. Pain relief was assessed in the immediate postoperative period when the pain was largely nociceptive, and at one month after surgery in the same 21 patients who developed post-thoracotomy neuropathic pain. The dose of buprenorphine required to provide 50% pain relief for neuropathic pain was almost twice the dose required for nociceptive pain.

A recent systematic review of high-quality RCTs involving eight studies lasting up to eight weeks each demonstrated clinically important efficacy (40). These studies demonstrated, on average, a 20% to 30% reduction in pain intensity. RCTs in patients with postherpetic neuralgia given controlled-release oxycodone (41) or controlled-release morphine (42) showed a significant reduction in pain intensity with variable improvement in sleep and disability. Trials of controlled-release oxycodone in painful diabetic neuropathy showed more consistent improvement in pain, sleep and ability to function (43,44).

Tramadol is a unique analgesic agent that mimics some of the properties of tricyclic antidepressants in that it inhibits reuptake of noradrenaline and serotonin. Tramadol also shows low-affinity binding for the µ opioid receptor, which allows it to be a weak opioid agonist (45). Tramadol has been studied in three RCTs involving patients with painful diabetic neuropathy and mixed neuropathic pain syndromes, and provides an overall NNT of 3.9 (20).

Methadone is a synthetic opioid analgesic that may be particularly useful in the management of neuropathic pain due to its NMDA antagonist properties (46). Methadone is also attractive because it has excellent oral bioavailability, duration of action of at least 8 h with repetitive dosing and availability
Tetrahydrocannabinol and cannabidiol in the drug for trigeminal neuralgia (55).

Baclofen is a muscle relaxant that may be a useful second-line sympathetic blocker, showed benefit in a painful diabetic neuropathic pain trials (20). Clonidine, an alpha-2 agonist subsequent response to oral mexiletine (53). However, mexiletine lasts several hours. This response has been the basis for starting 5 mg/kg over 30 min to 60 min may produce analgesia that duration of action. An intravenous infusion of lidocaine sites at lower concentrations than are required for conduction blockade. Local anesthetics suppress ectopic neural pacemaker rhythms agents whose mechanism of action is sodium channel blocker, has been shown to be useful in a variety of focal neuropathic pain syndromes with an NNT of 4.4 (20). Although the 5% lidocaine patch is not available in Canada, the gel or cream at a concentration of 5% or 10% can be made up by pharmacists.

Several topical combination products have been evaluated in neuropathic pain. Topical doxepin, capsaicin and their combination showed benefit (51), whereas a trial of topical amitriptyline 2% and ketamine 1%, used alone or in combination, produced negative results (52).

Topical lidocaine is probably the drug of first choice for an elderly patient with a focal painful neuropathy such as postherpetic neuralgia, because side effects are usually negligible. When all first-line medications have failed, tramadol (available in Canada combined with acetaminophen as Tramacet [Janssen-Ortho Inc, Canada]) may be useful. Failure of tramadol necessitates a trial of a major opioid analgesic. In fact, it is reasonable to initiate a short-acting opioid such as oxycodone with acetaminophen (Percoct, Bristol-Myers Squibb Canada) for breakthrough pain during titration of first-line agents. If one or more adjuvant analgesics provide adequate pain relief, the requirement for breakthrough medication should decrease. On the other hand, if there is no response to adjuvant analgesics, the total daily dose of the short-acting opioid provides guidance as to the initial maintenance dose in switching to a controlled-release opioid analgesic. Particularly intractable pain may require treatment with an anticonvulsant, an anticonvulsant and an opioid analgesic. Support for combination pharmacotherapy comes from a recent study reporting enhanced analgesia with a morphine-gabapentin combination relative to either drug alone (60). Table 2 provides dosing regimens for selected agents for neuropathic pain.

INVASIVE TECHNIQUES IN THE MANAGEMENT OF NEUROPATHIC PAIN

Interventional techniques for pain management are usually considered when standard pharmacological treatments fail and psychological screening shows emotional stability. However, interventional techniques are costly and labour intensive.
Continuous spinal infusion of an opioid or clonidine via an implantable pump may be salutary (61). Longitudinal studies of spinal cord stimulation have consistently shown significant pain relief in 50% to 60% of patients with neuropathic pain (62) affecting the extremities. The stimulation must cover the area of pain and, if the electrodes migrate, pain control may be lost necessitating surgical revision.

**PREVENTION OF NEUROPATHIC PAIN AND NEW TREATMENT STRATEGIES**

Presently, only approximately 50% of patients realize adequate relief from neuropathic pain (5). Preventive techniques and novel treatment strategies are obviously needed to improve outcome. The use of antiviral drugs in the first 72 h following development of a zoster rash does not reliably prevent postherpetic neuralgia, but can decrease the prevalence of pain at six months postinfection by 50% (63). A recent RCT involving a zoster vaccine reduced the incidence of postherpetic neuralgia by two-thirds, but this is a long-term treatment strategy that would require a massive vaccination program and evaluation of cost-effectiveness (64).

There are likely genetic determinants of neuropathic pain that target those individuals who are at greatest risk following nerve injury. Identification of these patients may allow more aggressive early management of this patient population (65). There is emerging evidence that nerve injury results in microglial activation in the dorsal horn. This triggers the release of pronociceptive cytokines, including neurotrophic factors, that can enhance nociceptive transmission and central sensitization. A specific cytokine antagonist may prevent the development of neuropathic pain (66).

**SUMMARY**

The present review summarizes the epidemiology, clinical features, pathophysiology, differential diagnosis and management of neuropathic pain. It specifically details an evidence-based approach to the pharmacological management of this disabling condition. Antidepressants and anticonvulsants provide frontline treatments for neuropathic pain. Topical lidocaine is sometimes useful for focal neuropathies such as postherpetic neuralgia. When adjuvant analgesics fail, opioid analgesics are important avenues of treatment. Pharmacological treatments provide adequate pain relief in approximately 50% of cases. Prevention strategies and novel treatment approaches are required to improve our management of neuropathic pain.
REFERENCES


ERRATUM


In this paper, the adverse effects of tramadol in Table 2 were incorrectly attributed to lidocaine. The adverse effects of tramadol should have included nausea, constipation, somnolence and headache. Please visit <www.pulsus.com> to view the corrected version of this paper. Pulsus Group extends apologies to the author for this error.
Submit your manuscripts at http://www.hindawi.com